They have claimed that knockdown of HDAC1 by specific siRNAs can suppress the proliferation and migration of breast cancer cells and inhibit the expression of IL-8, suggesting that HDAC1 may be a potential therapy target for breast cancer treatment. Here, CXCL8 is linked to breast carcinoma.